---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008525"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:18:29.219740+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma Q1 2022 revenue $5.9M; cash $192.1M; STRO-002 data expected H2 2022

## Summary
- Revenue $5.9M vs $14.7M YoY; operating expenses $45.0M vs $33.7M; net loss not stated directly.
- Cash, cash equivalents and marketable securities $192.1M as of Mar 31, 2022; runway into H2 2023.
- Phase 1 dose-expansion data for STRO-002 (ovarian cancer) expected H2 2022; regulatory meetings planned mid-2022.
- First patient dosed in STRO-002 + bevacizumab combo trial; endometrial cohort enrolling.
- Tasly amended STRO-002 license: $25M upfront, up to $350M in milestones; Tasly to fund Greater China development.

## SEC filing metadata
- accession: 0000950170-22-008525
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017022008525/0000950170-22-008525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017022008525/stro-20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008525
- JSON: https://secwatch.observer/filing/0000950170-22-008525.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.